clinical trial · NCT06714864
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
Catheter-Related Infections(taurolidine and heparin) catheter lock solutionStandard of Care
brief summary
This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.
started
Jul 8, 2025
primary completion
Jul 1, 2028
completion
Apr 1, 2029
last updated
May 19, 2026
official title
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol